Eupraxia Reports 52-Week EoE Trial Data for EP-104GI
Eupraxia Pharmaceuticals reveals consistent 52-week data from RESOLVE trial, showing EP-104GI maintains clinical remission in eosinophilic esophagitis patients with strong safety profile.
Category : Search result: Eupraxia Pharmaceuticals
$20M in drugs missing from Health Canada stockpile
Health Canada refuses to explain how $20 million worth of pharmaceuticals vanished from national emergency stockpile. Transparency concerns raised.
Page 1 of 1